who is a candidate for glp-1 Good Weight Loss Trial? who is not a candidate

Peddada, S

This interaction seems less relevant in patients 2 and 3, who have AVP-D and were well-controlled with levothyroxine

This metabolic dysregulation is defined by systemically reduced levels of metabolites such as amino acids and fatty acids, leading to reduced TCA cycle activity and oxidative phosphorylation, which may ultimately be a major contributor to neuropsychiatric symptoms associated with reduced energy, such as fatigue and other cognitive impairments [43, 62]

Several companies already have novel drug candidates in the late stages of clinical trials that offer weekly or monthly dosing options instead of daily injections